Cargando…
Cell and gene therapy regulatory, pricing, and reimbursement framework: With a focus on South Korea and the EU
Ever since relevant bioengineering technologies have sufficiently matured to the platformizable commercialization stage, a slew of money has flocked to the cell and gene therapy market over the last few years, resulting in an abundance of clinical studies in the field. Newer modalities have brought...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9998493/ https://www.ncbi.nlm.nih.gov/pubmed/36908458 http://dx.doi.org/10.3389/fpubh.2023.1109873 |
_version_ | 1784903475591643136 |
---|---|
author | Lee, SungKyung Lee, Jong Hyuk |
author_facet | Lee, SungKyung Lee, Jong Hyuk |
author_sort | Lee, SungKyung |
collection | PubMed |
description | Ever since relevant bioengineering technologies have sufficiently matured to the platformizable commercialization stage, a slew of money has flocked to the cell and gene therapy market over the last few years, resulting in an abundance of clinical studies in the field. Newer modalities have brought up a string of regulatory and legislative tasks, such as developing guidelines and legislative rules to systematically regulate newer pharmaceutical products. Accordingly, another layer of legislation and guidelines tailored for cell and gene therapies has been introduced and is expected to evolve on par with technological progress. Furthermore, authorities have shifted to pricing and reimbursement policies that can share risks for cost and outcome among stakeholders altogether, such as developers and the government, while expanding the accessibility of patients to innovative cell and gene therapies. This review attempts to capture the salient regulatory features of the cell and gene therapy market in the context of South Korea and the European Union and points out where two sovereign entities currently stand on each policy element and how each tackles regulatory challenges. We can observe the converging trend where regulatory, pricing and reimbursement rules of adjoining countries in the supranational union or member countries of a consortium are getting more aligned. Evidently, concerted efforts to share regulatory science knowledge and embrace reference pricing have played their parts. The authors argue that policy priorities should be placed on initiatives to harmonize with other medical authorities to better the rights of patients and clear out the uncertainties of developers, ultimately to share and advance regulatory science and layout forward-looking policies at opportune times. |
format | Online Article Text |
id | pubmed-9998493 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-99984932023-03-11 Cell and gene therapy regulatory, pricing, and reimbursement framework: With a focus on South Korea and the EU Lee, SungKyung Lee, Jong Hyuk Front Public Health Public Health Ever since relevant bioengineering technologies have sufficiently matured to the platformizable commercialization stage, a slew of money has flocked to the cell and gene therapy market over the last few years, resulting in an abundance of clinical studies in the field. Newer modalities have brought up a string of regulatory and legislative tasks, such as developing guidelines and legislative rules to systematically regulate newer pharmaceutical products. Accordingly, another layer of legislation and guidelines tailored for cell and gene therapies has been introduced and is expected to evolve on par with technological progress. Furthermore, authorities have shifted to pricing and reimbursement policies that can share risks for cost and outcome among stakeholders altogether, such as developers and the government, while expanding the accessibility of patients to innovative cell and gene therapies. This review attempts to capture the salient regulatory features of the cell and gene therapy market in the context of South Korea and the European Union and points out where two sovereign entities currently stand on each policy element and how each tackles regulatory challenges. We can observe the converging trend where regulatory, pricing and reimbursement rules of adjoining countries in the supranational union or member countries of a consortium are getting more aligned. Evidently, concerted efforts to share regulatory science knowledge and embrace reference pricing have played their parts. The authors argue that policy priorities should be placed on initiatives to harmonize with other medical authorities to better the rights of patients and clear out the uncertainties of developers, ultimately to share and advance regulatory science and layout forward-looking policies at opportune times. Frontiers Media S.A. 2023-02-24 /pmc/articles/PMC9998493/ /pubmed/36908458 http://dx.doi.org/10.3389/fpubh.2023.1109873 Text en Copyright © 2023 Lee and Lee. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Public Health Lee, SungKyung Lee, Jong Hyuk Cell and gene therapy regulatory, pricing, and reimbursement framework: With a focus on South Korea and the EU |
title | Cell and gene therapy regulatory, pricing, and reimbursement framework: With a focus on South Korea and the EU |
title_full | Cell and gene therapy regulatory, pricing, and reimbursement framework: With a focus on South Korea and the EU |
title_fullStr | Cell and gene therapy regulatory, pricing, and reimbursement framework: With a focus on South Korea and the EU |
title_full_unstemmed | Cell and gene therapy regulatory, pricing, and reimbursement framework: With a focus on South Korea and the EU |
title_short | Cell and gene therapy regulatory, pricing, and reimbursement framework: With a focus on South Korea and the EU |
title_sort | cell and gene therapy regulatory, pricing, and reimbursement framework: with a focus on south korea and the eu |
topic | Public Health |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9998493/ https://www.ncbi.nlm.nih.gov/pubmed/36908458 http://dx.doi.org/10.3389/fpubh.2023.1109873 |
work_keys_str_mv | AT leesungkyung cellandgenetherapyregulatorypricingandreimbursementframeworkwithafocusonsouthkoreaandtheeu AT leejonghyuk cellandgenetherapyregulatorypricingandreimbursementframeworkwithafocusonsouthkoreaandtheeu |